Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06805409

VExUS in Ards Patients and Association with AKI

A single-center prospective observational study will be conducted with the aim of determining the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Acute kidney injury (AKI) is common in patients with acute respiratory distress syndrome (ARDS) and is associated with higher mortality rates. Among the mechanisms underlying this AKI, venous congestion seems to be significant. However, methods for assessing congestion are limited and may be unreliable. The use of venous Doppler (inferior vena cava, suprahepatic veins, portal vein, and intrarenal veins) for grading the severity of congestion using the Venous Excess Ultrasound Score (VExUS) could potentially enable the earlier identification of ARDS patients with congestion.

A prospective observational monocenter study will be conducted with the objective to determine the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

The primary outcome measure will be the proportion of patients with a VExUS score ≥ 1 within 48 hours following the initiation of invasive mechanical ventilation. The secondary objective is to evaluate the association of different VExUS grades with the occurrence of the composite endpoint of major kidney events at Day 30 (MAKE-30), defined as the occurrence of death, dependence on dialysis, or persistent elevation of creatinine ≥ 200% of baseline creatinine.

The study involves adult patients admitted to the intensive care unit with moderate to severe ARDS requiring mechanical ventilation for less than 48 hours and requiring hemodynamic support with catecholamines. Within 48 hours of initiating invasive mechanical ventilation, concurrently with the cardiac ultrasound, the multi-site venous Doppler will be performed. Demographical, clinical, and biological data will be prospectively collected. The multi-site venous Doppler will be repeated on Day 7 of mechanical ventilation initiation or during catecholamine weaning, depending on which event occurs first. Patients will be followed for the entire duration of their intensive care unit stay. For patients discharged alive from the intensive care unit, follow-up will continue until 3 months after discharge to assess the occurrence of chronic kidney disease following the initial hospitalization.

No other investigations are mandated by the protocol besides performing the multi-site venous Doppler.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients ≥18 years old
  • Moderate to severe ARDS according to the Berlin definition
  • Requiring catecholamine support
  • Undergoing invasive mechanical ventilation for less than 48 hours

Exclusion criteria

  • Patients presenting with acute kidney injury KDIGO III requiring renal replacement therapy before the initial ultrasound evaluation
  • Requirement for veno-venous or veno-arterial ECMO circulatory support before inclusion
  • Patients with end-stage chronic kidney disease, on dialysis, and/or kidney transplant recipients
  • History of Child C cirrhosis and/or liver transplantation and/or portal hypertension
  • History of portal thrombosis
  • Known history of pulmonary hypertension
  • Pregnant women
  • Patients under legal protection
  • Patients who have expressed opposition to participating in the research

Treatment and study plan

Primary outcomes

  1. Proportion of VExUS score ≥ 1 within 48 hours of invasive mechanical ventilation.

    Time frame: 48 hours, 7 days after mechanical ventilation

    Quantification of the VExUS score from the measurement of the inferior vena cava size, an assessment of suprahepatic venous flow, portal venous flow and intra-renal venous.

Secondary outcomes

  1. Occurrence of the composite endpoint of major kidney events at Day 30 (MAKE-30).

    Time frame: 30 days

    defined as death, dependence on dialysis, or persistence of a creatinine elevation ≥ 200% of baseline creatinine.

Study contacts

Contact information is provided by the study sponsor or research team.

Armand MEKONTSO DESSAP, MD

CONTACT

[email protected]

+ 33 1 45 17 85 06

Romain ARRESTIER, PHD

CONTACT

[email protected]

+ 33 1 45 17 85 06

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Evaluation of Venous Congestion Using Doppler and Venous Excess Ultrasound Score (VExUS) During Acute Respiratory Distress Syndrome and Its Association with Acute Kidney Injury

Acronym: VEXAKI

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Feb 3, 2025
Registry last updated
Feb 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.